STAT News

STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem

Alnylam is heavily dependent on its heart drug Amvuttra for growth — and sales have been slowing.

By STAT News

1 min read
STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights